Antihypertensive and hypolipidemic effects of DC-015, a novel, potent and specific α1-adrenoceptor antagonist: Comparison with prazosin in spontaneously hypertensive rats
- 21 Downloads
The hypotensive effect of DC-015, a newly synthesized quinazoline derivative, was investigated and compared with prazosin in spontaneously hypertensive rats (SHR). Intravenous administration of DC-015 and prazosin (both at 0.01, 0.05 and 0.1 mg/kg) induced a dose-dependent reduction of mean arterial pressure (MAP) which reached a maximal effect at 5 min after injection and persisted over 2 h in SHR. Furthermore, at higher doses DC-015 (0.1 mg/kg i.v. and 2.0 mg/kg orally, respectively) did not cause any significant changes in heart rate (HR); whereas the same doses of prazosin (0.1 mg/kg i.v. and 2.0 mg/kg orally, respectively) produced a decrease in HR which seems to parallel the time course of the hypotensive response in SHR. DC-015 and prazosin attenuated pressor responses to phenylephrine (10 µg/kg) but failed to inhibit the pressor effects of angiotensin II (0.5 µg/kg) even at the maximal hypotensive dose (0.1 mg/kg). This observation indicates that DC-015 appears to exert its hypotensive effect through α1-adrenoceptor blockade. On the other hand, in SHR fed a high-fat-high-cholesterol (HF-HC) diet, oral administration of DC-015 and prazosin (both at 1.0 mg/kg, twice a day) for 4 weeks caused significant reductions in total plasma cholesterol (CE), low-density lipoprotein (LDL)-cholesterol and total plasma triglyceride (TG). DC-015 therapy also increased high-density lipoprotein (HLD)-cholesterol levels, thus the ratio of total plasma cholesterol to HDL-CE was improved. In contrast, prazosin did not significantly increase the HDL-CE level in this study. It is concluded that DC-015 decreased MAP, plasma CE, LDL-CE, plasma TG and increased HDL-CE levels. DC-015 may have therapeutic potential as a potent antihypertensive drug via the α1-adrenoceptor antagonist. Concurrently, DC-015 may thus hold some advantage for the reduction of two of the major risk factors, hypertension and hyperlipidemia, for cardiovascular diseases.
Key Wordsα1-Adrenoceptor antagonist DC-015 Prazosin Hypotensive effect Hyperlipidemia
Unable to display preview. Download preview PDF.
- 1.Cambridge D, Davey MJ, Massingham R. The pharmacology of antihypertensive drugs with special reference to vasodilators, α1-adrenergic blocking agents and prazosin. Med J Aust 5 (suppl 2):2–5;1977.Google Scholar
- 2.Campbell SF, Davey M. Doxazosin. A case history. J Drug Design Deliv 1:83–89;1986.Google Scholar
- 5.Chern JW, Tao PL, Yen MH, Lu GY, Shiau CY, Lai YJ, Chien SL, Chan CH. Studies on quinazolines. 5. 2,3-Dihydroimidazo[1,2-C]-quinazoline derivatives: A novel class of potent and selective α1-adrenoceptor antagonists and antihypertenisve agents. J Med Chem 36:2196–2207;1993.CrossRefPubMedGoogle Scholar
- 9.De Champlain J, Cousineau D, Lapointe L, Lavallee M, Nadeau R, Denis G. Sympathetic abnormalities in human hypertension. Clin Exp Hyperten 3:417–425;1981.Google Scholar
- 18.Krzesinski JM, Carlier PG, Rorive GL. Interrelationship of hypertension, plasma lipid and atherosclerosis. Drug 36(suppl 2):18–26;1988.Google Scholar
- 22.Person B, Yao T, Thoren P. Correlation between decreased heart rate and central inhibition of sympathetic discharges after prazosin administration in the spontaneously hypertensive rat. Clin Exp Hypertens 4:245–250;1981.Google Scholar
- 24.Timmermans BMWM, Van Zwieten PA. α-Adrenoceptor agonists and antagonists. Drug Future 9:41–55;1984.Google Scholar
- 28.Wallace RB, Hunninghake DB, Chambless LE, Heiss G, Wahl P, Barett-Connor E. A screening survey of dyslipoproteinemias associated with prescription drug use. The Lipid Research Clinics Program Prevalence Study. Circulation 73(suppl):I-70–I-79;1986.Google Scholar
- 31.William H, Karge III BS, Edward JW, Mark CK, Rorert MG, Robert J. Effects of prazosin on hemodynamics, hemostasis, and serum lipid and lipoprotein levels in normal and hypercholesterolemic monkeys. Am J Med 86(suppl 1B):19–23;1989.Google Scholar
- 32.Zwieten PA. α-Adrenoceptor antagonists. In: Ganten D, Mulrow PJ, eds. Handbook of Experimental Pharmacology: Pharmacology of Antihypertensive Therapeutics. New York, Springer, 105–125;1990.Google Scholar